



Guinea-Bissau

WUENIC 2025 revision,
Published 15 July 2026



WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2025 revision

Every year, WHO and UNICEF jointly review submissions from Member States on national immunization coverage, including annual administrative and official coverage, finalized survey reports and data from both published and grey literature. The data is triangulated with consideration of potential biases and local expert opinions to differentiate between accurately reflective empirical data and potentially misleading data, to assess the most likely coverage levels for each country.

WHO and UNICEF produce country-specific estimates by reviewing each country's data independently, without borrowing from other countries when data are missing. The estimates are not ad hoc adjustments to reported figures and may rely on a single empirical source, typically nationally reported coverage. When no data exist for a specific country-vaccine-year, earlier and later data are interpolated. If sources conflict or vary widely, the most plausible estimate is selected after considering potential biases.

This slide deck presents the latest WUENIC estimates (published 15 July 2026), using UNPD World Population Prospects (WPP 2024) for population-weighted averages and to derive absolute numbers of vaccinated and unvaccinated/zero-dose children.

Methods: • [Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes.](#)

- [Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach.](#)
- [Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage.](#)
- [Danovaro-Holliday et al. 2021. Compliance of WUENIC with Guidelines for Accurate and Transparent Health Estimates Reporting \(GATHER\) criteria.](#)

Definitions of immunization terms

Vaccine coverage

Percentage of infants (children under one year of age) who received certain vaccine-doses. For example, coverage of DTP3 is the percentage of infants who received all three doses of diphtheria, tetanus, and pertussis (DTP) vaccine.

Unvaccinated

An infant that did not receive the first dose of a vaccine series. The term zero-dose is used to describe children unvaccinated with DTP1.

Under-vaccinated

An infant who received some but not all the recommended vaccine-doses in the national schedule.

Vaccine-Doses

- Bacillus Calmette-Guerin (BCG): vaccine against tuberculosis
- Hepatitis B birth dose, given within 24 hours after birth (HepBB)
- Diphtheria, tetanus, and pertussis vaccine, first dose (DTP1) and third dose (DTP3)
- Hepatitis B vaccine, third dose (HepB3)
- Haemophilus influenzae type b vaccine, third dose (Hib3)
- Inactivated polio vaccine, first dose (IPV1) and last dose (IPVC)
- Measles containing vaccine, first dose (MCV1) and second dose (MCV2)
- Rotavirus vaccine, last dose (RotaC)
- Pneumococcal vaccine, last dose (PCVC)
- Yellow Fever vaccine (YFV)
- Meningococcal A vaccine (MengA)
- Human papillomavirus vaccine, first dose (HPV1) and last dose (HPVc): vaccine to protect against certain types of human papillomavirus that can lead to cancer or genital warts

The Immunization Agenda 2030 (IA2030)

The IA2030 is a global strategy endorsed by the World Health Assembly aiming to ensure everyone, everywhere, at every age benefits from vaccines for improved health and well-being by 2030. It focuses on increasing vaccine coverage, equity, sustainability and pandemic preparedness while promoting life-course immunization and integrating immunization with other health services.

Key concepts

- The World Health Organization (WHO) provides global vaccine recommendations, which are adapted by countries based on local needs. Only DTP, polio and measles-containing vaccines are used in all countries.
- DTP1 is a marker of access to routine immunization services, and when not received, serves as a proxy for identifying children who have not received any vaccinations, also known as "zero-dose" children. High DTP1 coverage indicates good access to immunization services, while low coverage suggests challenges in reaching children with essential vaccines.
- DTP3 is a widely used indicator of immunization programme performance. It reflects a country's ability to deliver routine immunization services and ensures children are protected against serious disease. DTP3 is tracked globally and serves as a key measure of a nation's vaccination efforts.
- DTP1-DTP3 drop-out measures the percentage of children who received DTP1 but not DTP3, and highlights where children are lost along the vaccination pathway, highlighting potential weaknesses in service delivery and follow-up.
- MCV1 (usually recommended between 9-12 months) assesses the ability to deliver vaccines later in infancy. It serves as a tracer for protection against measles and is a good indicator of health system performance.
- HPV vaccine protects against specific types of human papilloma virus (HPV), and is used to measure life cycle vaccination.
- Other key indicators include PCVC and MCV2, which are used to monitor the Sustainable Development Goals (SDGs).
- Together, these indicators provide a consistent and comparable way to track immunization progress, identify missed communities and monitor global targets, including those under the Immunization Agenda 2030 (IA2030) and Sustainable Development Goals (SDGs).

Key messages

- DTP1 coverage increased 1 percentage point from 89% in 2024 to 90% in 2025.
- DTP3 coverage declined 1 percentage point from 85% in 2024 to 84% in 2025.
- There were <1,000 fewer zero-dose children in 2025. This leaves 6,000 children without vaccination, vulnerable to vaccine-preventable diseases and a further 4,000 with incomplete protection.
- Guinea-Bissau accounted for 0.2% of zero-dose children in West and Central Africa (WCAR) and <0.1% of zero-dose children globally.
- MCV1 coverage declined 7 percentage points from 76% in 2024 to 69% in 2025. There were 20,000 children who missed out on the first measles vaccination.
- MCV2 coverage declined 9 percentage points from 45% in 2024 to 36% in 2025.
- The Human papillomavirus (HPV) vaccine was not introduced.

Vaccination schedule, 2025

Level	Vaccine	Dose number and age administered			
		1	2	3	4
National	BCG	Birth			
National	DTWPHIBHEPB	6 weeks	10 weeks	14 weeks	
National	IPV			14 weeks	
National	MEASLES	9 months	15-23 months		
National	MenA	9 months			
National	OPV	Birth	6 weeks	10 weeks	14 weeks
National	PCV	6 weeks	10 weeks	14 weeks	
National	Rotavirus	6 weeks	10 weeks		
National	YF	9 months			

This table shows the 2025 national immunization schedule for routine services in Guinea-Bissau, reported through the WHO/UNICEF Joint Reporting Form on Immunization (JRF).

Each row corresponds to a vaccine or combination vaccine, indicating whether it is delivered at the national or subnational level. The schedule outlines the number of doses and the recommended ages for administration. Only childhood and adolescent vaccines relevant to WUENIC are included.

Vaccine introduction years

Vaccine	National introduction
HPV (Human papillomavirus) vaccine	Not introduced
HepB birth dose	Not introduced
Hepatitis B vaccine	2008
Hib (Haemophilus influenzae type B) vaccine	2008
IPV (Inactivated polio vaccine)	2016
IPV (Inactivated polio vaccine) 2nd dose	Not introduced
Malaria vaccine	Not introduced
Measles-containing vaccine 2nd dose	2022
Meningococcal meningitis vaccines (any strain)	2023
Mumps vaccine	Not introduced
PCV (Pneumococcal conjugate vaccine)	2015
RSV (Respiratory syncytial virus) immunization strategy	Not introduced
Rotavirus vaccine	2012
Rubella vaccine	Not introduced
Typhoid conjugate vaccine	Not introduced

This table displays the year each vaccine was introduced in Guinea-Bissau. If a vaccine has been suspended, no introduction year is shown, but if it was suspended and later reintroduced, the year of reintroduction is provided. The introduction years can reflect nationwide rollout, partial (subnational) rollout, or introduction targeted to specific risk groups or high-risk areas, as indicated in the column headers.

Vaccine stockouts


Vaccines / supplies	2021	2022	2023
BCG	National (12m) and subnational	National (3m) and subnational	
OPV	National (12m) and subnational	National and subnational	National (1m) and subnational
Rotavirus	National (12m) and subnational		

This table presents reported vaccine stockouts of childhood vaccines relevant to WUENIC at the national and subnational levels over the last 5 years (2021 to 2025). Where available, the duration of national-level stockouts is indicated in months. Subnational stockouts are noted without specifying duration. Only vaccines that had a stockout during the specified time period are displayed.

A stockout refers to a period when vaccine storage and distribution points (e.g., national or district stores) are fully depleted, including buffer stock, and are unable to supply vaccines to lower-level stores or facilities. It is important to note that facility-level stockouts can still occur even when upper-level stores have inventory. Stockouts, especially prolonged ones, can negatively impact immunization coverage.

In 2025, coverage increased for two antigens, remained unchanged for two, and declined for eight, indicating limited improvement in routine immunization performance; two achieved at least 90% coverage.

Vaccine coverage, Guinea-Bissau, 2000-2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision.
Note: Stock information available from 2003.
An asterisk (*) indicates where there was a vaccine stockout at the national or subnational level.


This heatmap shows trends in vaccine coverage since 2000, with green cells indicating coverage of 90% or more.

In 2025, 2 out of 12 (17%) vaccines in the schedule achieved coverage of 90% or more. Vaccine coverage ranged from 36% to 90%.

Since 2008, estimates have been made for 8 new vaccines. MengA is the newest vaccine reported (2023), which achieved 65% coverage in 2025.

In 2025, Guinea-Bissau did not report any stockouts of vaccines or supplies.

Coverage of key childhood vaccines (%), Guinea-Bissau, 2000-2025



This chart shows coverage trends for the DTP and measles vaccines. These are key antigens for assessing national immunization programmes.

In 2025, DTP1 coverage (a proxy for access to immunization services) was 69%.

DTP3 coverage - a marker of how well countries are delivering immunization services to children - was below the 90% target set for 2030.


WHO recommends that countries achieve at least 95% coverage with both the first (MCV1) and second (MCV2) doses of measles-containing vaccine. MCV1 provides initial protection and MCV2 ensures long-term immunity and closes gaps in coverage.

In 2025, MCV1 coverage was below the 95% target and MCV2 coverage was below the 95% target.

Between 2024 and 2025, 1 vaccines increased coverage, 3 declined and 0 remained the same.

Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision

Vaccine coverage compared with other countries in the region, WCAR, 2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Country ISO codes displayed. Coverage in gnb shown in the headers. Regional average coverage shown by the dashed line.

DTP1


In 2025, DTP1 coverage was 90% and DTP3 was 84%, leaving 10,000 children un- or under-vaccinated, including 6,000 zero-dose and 4,000 with only partial protection.

The key goal of the Immunization Agenda 2030 is to make vaccination available to everyone, everywhere, by 2030.

This chart shows diphtheria, tetanus and pertussis-containing vaccine first (DTP1) and third dose (DTP3) coverage trends, the number of zero-dose children and DTP drop-out in Guinea-Bissau.



In 2025, DTP1 coverage in Guinea-Bissau remained relatively constant within 1% at 90%. The number of children missing out on any DTP vaccination (zero-dose children) improved from 7,000 in 2024 to 6,000 in 2025.

DTP3 coverage remained relatively constant within 1% at 84% in 2025, leaving 10,000 children vulnerable to vaccine-preventable diseases.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Lines show vaccine coverage and bars show number of children.
Zero-dose children are those who did not receive DTP1.

In 2025, Guinea-Bissau DTP1 coverage was 90% - this is 1 percentage point lower than in 2019 and the same as the global average.




In 2025, DTP1 coverage in Guinea-Bissau (90%) was the same as the global average and 9 percentage points higher than the average across all WCAR countries (81%).

National DTP1 coverage was 1 percentage point lower than in 2019 (91%).

This equates to 6,000 zero-dose children in 2025 compared to 5,000 zero-dose children in 2019.

Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Coverage difference compared to 2019 - values above zero indicate coverage higher than in 2019 and values below zero indicate coverage lower than in 2019

In 2025, Guinea-Bissau was among the countries with the highest coverage and was not among the top 10 countries with the highest number of zero-dose children in the region.




This chart shows DTP1 coverage in countries in WCAR from lowest to highest coverage, and the rank of the top 10 countries with the most zero-dose children, based on absolute numbers.

In 2025, Guinea-Bissau ranked number 13 out of 24 countries for lowest DTP1 coverage (based on tied ranks).

Guinea-Bissau was not in the top 10 countries with the most zero-dose children.

Note: Large cohort countries may have high numbers of zero-dose children despite high vaccine coverage. It is important to consider both coverage and absolute numbers of unvaccinated children to ensure vulnerable countries with small birth cohorts are not overlooked.

Countries ranked by number of zero-dose children, WCAR, 2021-2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
 Note: Number in parentheses is the number of zero-dose children.


This chart compares the ranking of countries in the region based on the absolute number of zero-dose children, with rank 1 representing the country with the most zero-dose children.

In 2021, Guinea-Bissau ranked number 22 out of 24 countries with 6,000 zero-dose children.

In 2025, Guinea-Bissau ranked number 22 out of 24 countries with 6,000 zero-dose children.

Note: Absolute numbers of zero-dose children is based on a combination of programme performance and surviving infant target population size. Countries may climb to a higher rank despite a decline in number of zero-dose children as the ranking also depends on performance of other countries in the region.

More children need to be vaccinated each year to achieve the IA2030 goal of halving the number of zero-dose children by 2030, with a projected small increase in surviving infants.



Sources: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision; United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024, Online Edition.
Note: The Immunization Agenda 2030 (IA2030) calls on all countries to reduce the number of zero dose children in 2019 by half by 2030.


IA2030 calls on all countries to reduce the number of zero dose children in 2019 by half by 2030. This chart shows the annual number of children required to be vaccinated to reach the ZD target.

IA2030 calls on all countries to reduce the number of zero dose children in 2019 by half by 2030. This chart shows the annual number of children required to be vaccinated to reach the ZD target.

Guinea-Bissau is projected to have a small increase (<10,000) in the number of surviving infants by 2030. Therefore, to achieve the IA2030 ZD target, more (~2.07%) children need to be vaccinated with DTP1 each year.

In 2025, the number of zero-dose children was 56% above the annual IA2030 goal, putting the 2030 goal at serious risk without accelerated action.

Estimated number of zero-dose children, 2000-2025 and target by 2030, Guinea-Bissau



IA2030 aims to leave no one behind with immunization and calls on all countries to reduce the number of zero dose children by half by 2030.

- This chart shows:
- Estimated number of zero-dose children in 2000-2025 (dark blue bars)
 - Zero-dose target by 2030 (light blue bar)
 - Trajectory to reach the 2030 target based on a linear decline (points)

In 2025, the number of zero-dose children was approximately 56% higher than the annual number proposed to reach the target, based on a linear trajectory of decline.

Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: The Immunization Agenda 2030 (IA2030) calls on all countries to reduce the number of zero dose children in 2019 by half by 2030. Dark blue bars are the estimated number of zero-dose children in 2000-2025, light blue bar is the target number of zero-dose children by 2030. The line and points show the yearly progress and trajectory to meet the target by 2030, based on a linear decline.

For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.

DTP1 coverage in 2025 (90%) was relatively constant within 1% compared to 2019 (91%).


The number of children vaccinated with DTP1 increased 4% compared to in 2019.

The number of surviving infants increased approximately 5% compared to in 2019.

In 2025, more children were vaccinated than in 2019.

In 2025, there were more surviving infants (target population) than in 2019.


For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision

DTP3


In 2025, Guinea-Bissau DTP3 coverage was 84% - this is the same as in 2019 and 1 percentage point lower than the global average (85%).



In 2025, DTP3 coverage in Guinea-Bissau (84%) was 1 percentage point lower than the global average (85%) and 13 percentage points higher than the average across all WCAR countries (71%).


National DTP3 coverage was the same as in 2019 (84%).

This equates to 10,000 un- and undervaccinated children in 2025 - the same number of un- and undervaccinated children as in 2019.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Coverage difference compared to 2019 - values above zero indicate coverage higher than in 2019 and values below zero indicate coverage lower than in 2019

In 2025, Guinea-Bissau was among the countries with the highest coverage and was not among the top 10 countries with the highest number of un- and undervaccinated children in the region.



This chart shows DTP3 coverage in countries in WCAR from lowest to highest coverage, and the rank of the top 10 countries with the most un- and undervaccinated children, based on absolute numbers.

In 2025, Guinea-Bissau ranked number 13 out of 24 countries for lowest DTP3 coverage (based on tied ranks).

Guinea-Bissau was not in the top 10 countries with the most un- and undervaccinated children.

Note: Large cohort countries may have high numbers of un- and undervaccinated children despite high vaccine coverage. It is important to consider both coverage and absolute numbers of unvaccinated children to ensure vulnerable countries with small birth cohorts are not overlooked.

For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.

DTP3 coverage in 2025 (84%) was the same as in 2019 (84%).


The number of children vaccinated with DTP3 increased 5% compared to in 2019.

The number of surviving infants increased approximately 5% compared to in 2019.

In 2025, more children were vaccinated than in 2019.

In 2025, there were more surviving infants (target population) than in 2019.


For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Unvaccinated includes zero-dose and undervaccinated children

MCV1

MCV1 coverage declined at from 76% in 2024 to 69% in 2025 - below the 95% level needed to prevent outbreaks and, leaving 20,000 children without any protection against measles. MCV2 coverage declined at from 45% in 2024 to 36% in 2025 - below the IA2030 target of 90%.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Lines show vaccine coverage and bars show number of children.


Measles, because of its high transmissibility, acts as a 'canary in the coalmine', quickly exposing any immunity gaps in the population. The coverage of measles containing vaccine (MCV) is thus often used as a tracer for protection.

The percentage of children receiving MCV1 – typically at 9 or 12 months depending on the national vaccination schedule – declined at 69%. This is lower than in 2019, where coverage was 83%.

20,000 children missed their routine first dose of measles vaccine.

MCV2 is typically administered to children between 18 months and five years old. MCV2 coverage declined at 36% in 2025.


In 2025, Guinea-Bissau MCV1 coverage was 69% - this is 14 percentage points lower than in 2019 and 15 percentage points lower than the global average (84%).



In 2025, MCV1 coverage in Guinea-Bissau (69%) was 15 percentage points lower than the global average (84%) and 5 percentage points higher than the average across all WCAR countries (64%).


National MCV1 coverage was 14 percentage points lower than in 2019 (83%).

This equates to 20,000 unvaccinated children in 2025 compared to 10,000 unvaccinated children in 2019.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: Coverage difference compared to 2019 - values above zero indicate coverage higher than in 2019 and values below zero indicate coverage lower than in 2019

In 2025, Guinea-Bissau was among the countries with the highest coverage and was not among the top 10 countries with the highest number of unvaccinated children in the region.



This chart shows MCV1 coverage in countries in WCAR from lowest to highest coverage, and the rank of the top 10 countries with the most unvaccinated children, based on absolute numbers.

In 2025, Guinea-Bissau ranked number 11 out of 24 countries for lowest MCV1 coverage (based on tied ranks).

Guinea-Bissau was not in the top 10 countries with the most unvaccinated children.

Note: Large cohort countries may have high numbers of unvaccinated children despite high vaccine coverage. It is important to consider both coverage and absolute numbers of unvaccinated children to ensure vulnerable countries with small birth cohorts are not overlooked.

For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.

MCV1 coverage in 2025 (69%) was lower than in 2019 (83%).


The number of children vaccinated with MCV1 decreased 13% compared to in 2019.

The number of surviving infants increased approximately 5% compared to in 2019.

In 2025, fewer children were vaccinated than in 2019.


In 2025, there were more surviving infants (target population) than in 2019.

For vaccine coverage to increase, the number of children vaccinated must increase at a faster rate than the population increases.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision

In 2025, Guinea-Bissau reported no confirmed measles cases, while MCV1 coverage was 69% and MCV2 coverage was 36%.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision; Reported measles and rubella cases and incidence rates by WHO Member States, as of 12 June 2026. Provisional data based on monthly data reported to WHO (Geneva) as of 12 June 2026.

Note: Asterisks (*) indicate years with measles vaccine stockouts and carets (^) indicates years with measles vaccination campaigns (national or subnational).

In 2025, there was a total of 0 confirmed measles cases in Guinea-Bissau. In the same year, MCV1 coverage was 69% and MCV2 coverage was 36%.

The number of cases in 2025 was 100% lower than in 2024 (n=56).

The highest number of measles cases was reported in 2022 (n=144). In this year, MCV1 coverage was 84%.



Guinea-Bissau reported measles vaccine stockouts in 2004, 2008, 2015, 2017, and 2018.

There were measles-containing vaccine supplementary immunization activities/campaigns in 2024.

Childhood immunization: Additional charts

In 2025, DTP1-DTP3 drop-out was moderate (7%) and DTP1-MCV1 drop-out was high (23%) in Guinea-Bissau, indicating moderate ability to deliver the primary series early on, but poor ability to provide the full course of vaccines in infancy.

Zero-dose children are those who did not receive DTP1.



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Drop-out classification: <5% = low, 5-10% = medium, >10% = high

Drop-out rates show the percentage of children who received DTP1, but not DTP3/MCV1. Low drop-out rates indicate high retention of children in immunization programmes.


This chart shows trends in drop-out rates between DTP1 and DTP3, and DTP1 and MCV1.

In 2025, 7% of children who received DTP1 did not receive DTP3 (left), and 23% of children who received DTP1 did not receive MCV1 (right).

The medium DTP drop-out rate implies moderate ability to provide a complete series of vaccines early in life. The high DTP-MCV drop-out rate implies poor retention in immunization programmes and ability to provide a full course of vaccines in infancy (up to one year).

In 2025, Guinea-Bissau DTP drop-out was higher than the global rate, while DTP-MCV drop-out was higher than the global rate.

In 2025, Guinea-Bissau had its lowest coverage in MCV2 (36%), while most other routine vaccines clustered around 69-90%; 5 antigens decreased since 2019, and 6 antigens decreased since 2024.




This chart shows trends in coverage of selected core routine vaccines recommended in childhood.

In 2025, MCV2 had the lowest coverage (36%), followed by MCV1 (69%).

Compared to 2019, coverage of 5 vaccines decreased (BCG, DTP1, IPV1, MCV1 and YFV) and 2 vaccines remained constant (DTP3 and ROTAC).

Compared to 2024, coverage of 6 vaccines decreased (BCG, DTP3, IPV1, MCV1, MCV2 and YFV) and 2 vaccines increased (DTP1 and ROTAC).

Vaccine coverage (%), Guinea-Bissau, 2000-2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Numbers in the data label bubbles refer to vaccine coverage in the latest year estimates are available.


This chart shows trends in coverage of 7 vaccines (complete series).

In 2025, MCV2 had the lowest coverage of all vaccines (36%), followed by MCV1 (69%).

Coverage of 4 vaccines were the same (DTP3, HEPB3, HIB3 and ROTAC) and 2 vaccines decreased (IPV1 and MCV1) compared to respective coverage in 2019.

Coverage of 6 vaccines decreased (DTP3, HEPB3, HIB3, IPV1, MCV1 and MCV2) and 1 vaccine increased (ROTAC) compared to respective coverage in 2024.

Vaccine coverage (%), Guinea-Bissau, 2019-2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: The grey bar spans vaccine coverage across all years 2019-2025 and the dots represent coverage in specific years.
Coverage is shown for vaccines with data all years 2019-2025.
Vaccine names are coloured based on if coverage is lower (red), the same as (blue) or higher (green) than in 2019

This chart shows the range of coverage across all years 2019 to 2025 (grey bars), and coverage in specific years (dots), by vaccine. The chart can be used for assessing recovery to pre-pandemic levels.

DTP1 coverage declined between 2019 (91%) and 2024 (89%). DTP1 coverage increased in 2025 (90%) compared to 2024, and was lower than in 2019. In 2019-2025, DTP1 coverage was at it's lowest level in 2024 (89%).

In 2024, 6 vaccines had lower coverage than in 2019.


In 2025, 5 vaccines had lower coverage than in 2019.

In 2025, 7 vaccines had lower coverage than in 2024.

SDG 3.b.1

In 2025, Guinea-Bissau met the 90% SDG coverage target for PCVC, but not for the remaining vaccines.

SDG 3.b.1: Proportion of the target population covered by all vaccines included in their national programme, Guinea-Bissau, 2000-2025



Source: WHO/UNICEF Estimates of National Immunization Coverage, 2025 revision
Note: The four vaccination coverage indicators contribute to SDG indicator 3.b.1 are: DTP3, MCV2, PCVC and HPVc
The Immunization Agenda 2030 (IA2030) global target is 90% coverage of all four antigens by 2030.
Data are missing for vaccines that have not been introduced by the country or where estimates were not made (HPVc).

Four vaccination coverage indicators contribute to Sustainable Development Goal 3, indicator b.1: DTP3, PCV3, MCV2 and HPV.

The IA2030 global target is 90% coverage of all four antigens by 2030.

Guinea-Bissau has 3 out of the 4 SDG vaccines.


In 2025, Guinea-Bissau had achieved at least 90% coverage of 1 out of the 4 vaccines.

Additional resources

[illegible]

	A	B	C	D	E	F	G	H	I	J	
1	unicef	regio	iso3c	country	vaccine	year	target_grp	coverage	vaccinated	unvaccinated	target
2	ROSA	AFG		Afghanistan	bog	1982	births	10	57,000	514,000	571,000
3	ROSA	AFG		Afghanistan	bog	1983	births	10	56,000	503,000	559,000
4	ROSA	AFG		Afghanistan	bog	1984	births	11	62,000	501,000	563,000
5	ROSA	AFG		Afghanistan	bog	1985	births	17	100,000	490,000	591,000
6	ROSA	AFG		Afghanistan	bog	1986	births	18	107,000	489,000	596,000
7	ROSA	AFG		Afghanistan	bog	1987	births	27	161,000	434,000	595,000
8	ROSA	AFG		Afghanistan	bog	1988	births	40	238,000	358,000	596,000
9	ROSA	AFG		Afghanistan	bog	1989	births	38	233,000	380,000	614,000
10	ROSA	AFG		Afghanistan	bog	1990	births	30	191,000	446,000	637,000
11	ROSA	AFG		Afghanistan	bog	1991	births	21	134,000	505,000	640,000
12	ROSA	AFG		Afghanistan	bog	1992	births	19	127,000	541,000	668,000
13	ROSA	AFG		Afghanistan	bog	1993	births	17			760,000
14	ROSA	AFG		Afghanistan	bog	1994	births	15			852,000
15	ROSA	AFG		Afghanistan	bog	1995	births				899,000
16	ROSA	AFG		Afghanistan	bog	1996	births				932,000
17	ROSA	AFG		Afghanistan	bog	1997	births				962,000
18	ROSA	AFG		Afghanistan	bog	1998	births				986,000
19	ROSA	AFG		Afghanistan	bog	1999	births	36			1,013,000
20	ROSA	AFG		Afghanistan	bog	2000	births	30			1,037,000
21	ROSA	AFG		Afghanistan	bog	2001	births	43	432,000	574,000	1,007,000
22	ROSA	AFG		Afghanistan	bog	2002	births	46	467,000	548,000	1,015,000

UNICEF, WHO, World Bank, Gavi and
African Union regions



Additional immunization data resources can be found at:

<https://data.unicef.org/resources/immunization/>

*UNICEF, WHO, World Bank, Gavi and
African Union regions*

[illegible]

[Back to Top](#)

WUENIC Talking Points: Latin America and the Caribbean (LACR) Region

Revision Date: 2025

Contents

Overview	2
OTPI: Reaching zero-disease children	4
OTPI: A number of vaccine immunizations remain delivery to children	6
MNC: Country at the end line	8
HPV	10
Aperly	12

[Latin America and the Caribbean Region](#)

WUENIC Talking Points: Ethiopia

Revision Date: 2025

Contents

Overview	2
OTPI: Reaching zero-disease children	4
OTPI: A number of vaccine immunizations remain delivery to children	6
MNC: Country at the end line	8
HPV	10
Regional Comparison	1
Additional Resources	6
Appendix	10

[Ethiopia in the African region](#)

Overview

- While setting variations exist countries and vaccine rates, the 18 childhood vaccines achieved an average coverage of 85% in higher wealth, LACR region in 2023.
- Coverage of the first dose of diphtheria-tetanus-pertussis-containing vaccine (DTP1) was the lowest at 70% in a region in 2023. DTP2, and the third dose of DTP containing vaccine (DTP3) were the lowest at 60% and 50% respectively. Coverage of the measles vaccine against measles (MCV1) was the lowest in 2023 at 54% in 2024 (R16).
- The majority received 23 out of 25 WHO-recommended childhood vaccines at least one of the 18 childhood vaccine administered in the region.
- There were 1st vaccine, 2nd and 3rd vaccine of each BCG, measles, and vaccine (1st, 2nd, 3rd), Diphtheria, Tetanus, and Pertussis (DTP1, DTP2, DTP3), Polio (Polio1, Polio2, Polio3), and Measles (Measles1, Measles2, Measles3) in the region. The annual gap to achieve the immunization targets 2025 target of approximately the number of children (approximately 18 to 25) in LACR region is 17%.

Vaccine coverage (%) by year, LACR, 2008-2024

OTPI: Reaching zero-disease children

- In 2020, OTPI coverage in children was 51%, compared to 10% in 2015.
- In 2023, the number of zero-disease children in Ethiopia (2023) was approximately 10% higher than in 2015.
- There were 545,000 zero-disease children in the region in 2023 compared to 2015, with a significant increase in the number of zero-disease children in the region.
- There were 545,000 zero-disease children in the region in 2023 compared to 2015, with a significant increase in the number of zero-disease children in the region.
- Among Ethiopia and Southern Africa region states, Ethiopia ranked 1st out of 27 countries in 2023 (OTPI coverage in regional and national).
- OTPI coverage in Ethiopia in 2023 was 10%, a percentage points lower than in 2015. However, OTPI coverage may improve due to, provide a complete vaccine across the region.

OTPI coverage in children and zero-disease children

Revision Date: 2025

Interactive
WUENIC
country profiles
can be found at:

<https://worldhealthorg.shinyapps.io/wuenic-trends/>

Short feedback questionnaire

(5 minutes)

We are seeking your feedback on the global groupings (GAVI, African Union, World Bank Income, WHO and UNICEF) and country-level PowerPoint slides developed for the release of global immunization estimates. Your input will help us understand their usefulness and identify areas for improvement.

Please take a few moments to complete this short survey and have your voice heard:

<https://forms.office.com/e/Qv1HXxxNZQ>

